alexa EEG As A Pharmacodynamic Endpoint During Development Of A Novel Drug In Alzheimer?s Disease
ISSN: 2161-1025

Translational Medicine
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

2nd International Conference on Translational & Personalized Medicine
August 05-07, 2013 Holiday Inn Chicago-North Shore, IL, USA

Niclas Brynne
Accepted Abstracts: Transl Med
DOI: 10.4172/2161-1025.S1.010
Abstract
Electroencephalography (EEG) slowing is considered a hallmark of the neurodegenerative process and related deficits observed in Alzheimer?s patients. For patients with both mild and more advanced stages of AD, one commonly reported finding is an increased power in both delta and theta bands. Quantitative EEG provides viable and promising avenues for clinical investigation, with the aim of developing useful biomarker(s) of early cognitive decline. Recently, EEG has gained renewed interest among those interested in discovering and developing novel therapies, for several important reasons: (1) to establish central nervous system pharmacodynamic activity for novel compounds and (2) to potentially yield noninvasive and relatively low-cost biomarkers for key diseases, including AD. A novel analytical approach of EEG also includes the multivariate technique. This method uses pair wise comparison of groups where classifiers are developed from statistical pattern recognition (SPR) to a large set of EEG features. For each classifier, the SPR finds an optimal combination of the EEG features which separate the two groups under consideration. The accuracy, sensitivity, and specificity of each classifer is estimated using 10-fold cross validation. The technique also enables the development of a new way to monitor the physiological EEG changes, acetylcholine activity, and an index (Ach Index) has been constructed. The Ach Index was estimated from spectral and synchronization activity of the EEG. The significance of the novel method to analyze EEG will be discussed in relation to Phase I/II results of a new symptomatic drug for the treatment of Alzheimer ́s Disease.
Biography
Niclas Brynne has a Ph.D. in Clinical Pharmacology from the Karolinska Institute, Stockholm, Sweden. He is a senior leader with over 20 years experience in strategic leadership of global drug development from Pharmacia and AstraZeneca. He has been the Director for Translational Medicine Department for several years and led the development of biomarkers in the CNS area (Analgesia, Neurology and Psychiatry) as well as a number of novel projects for treatment of Alzheimer ́s Disease and Cognitive Disorders. He recently joined MentisCura, an innovative research company, as a senior VP. He is also a board member at the Stockholm Brain Institute.
image PDF   |   image HTML
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords